Needham raised the firm’s price target on Pacira (PCRX) to $32 from $30 and keeps a Buy rating on the shares after its Q1 earnings beat. The company’s Q1 volume was up 7%, in line with growth seen in 2025, as it continues to expect similar volume growth and improved pricing dynamics once final GPO contract lapses in the middle of this year, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- AI Models Turn More Positive on Pacira Pharmaceuticals as Cash Flow and Balance Sheet Strength Offset Valuation Concerns
- Pacira reports Q1 EPS 60c, consensus 56c
- Pacira backs FY26 revenue view $745M-$770M, consensus $760.65M
- PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exparel’s Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences